News

Wound-specific Bacteria May Be Targets for DEB Treatment

A distinct set of bacteria colonizes the skin in and around wounds in people with dystrophic epidermolysis bullosa (DEB), according to a new study. The finding suggests that these patients may benefit from therapies that specifically target those bacteria and that encourage the growth of non wound-associated bacteria instead.

Debra’s Smile Fund Program Open to All Ages for Mini Wishes

People of all ages with epidermolysis bullosa (EB) are invited to have their “mini wishes” — for things from iPads to concert tickets to birthday parties — granted by the Smile Fund Program. The Smile Fund program, created by the Dystrophic Epidermolysis Bullosa Research Association of America, known as…

Gentamicin Lessened Ocular Lesions in Junctional EB

Topical administration of the antibiotic gentamicin to the eye restored the production of a key skin health protein called laminin 332 while rapidly lessening eye lesions in a woman with junctional epidermolysis bullosa (JEB), a study reports. The study, “Topical gentamicin ointment induces LAMB3 nonsense mutation…

InMed Asking to Open Phase 2 Trial of INM-755, Cannabinol Cream for EB

InMed Pharmaceuticals has submitted applications to regulatory authorities in Austria, Israel, and Serbia, seeking clearance to begin clinical testing of its investigational cannabinol cream INM-755 in people with epidermolysis bullosa (EB). Similar applications to authorities in France, Germany, Greece, and Italy are expected in the coming weeks.

Amryt Pharma Advances Regulatory Applications for Filsuvez

Amryt Pharma has completed its rolling submission of an application to the U.S. Food and Drug Administration seeking the approval of Filsuvez (Oleogel-S10), a topical gel to heal skin wounds in people with junctional (JEB) and dystrophic epidermolysis bullosa (DEB). The new drug application (NDA) includes a request for priority review, which can…

Stem Cells Derived From Skin Show Early Potential to Treat RDEB

Skin-derived stem cells producing the ABCB5 protein outperformed those derived from bone marrow at migrating toward and integrating into wounds associated with recessive dystrophic epidermolysis bullosa (RDEB), a study reports. These cells also show a less pro-inflammatory potential, and their ability to modify the immune response may make them…